Humacyte, Inc. (HUMA)
$0.36-7.69%Close
SELLCRISIS · day 31
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $60M
- Beta
- 2.44
- P/E (TTM)
- -0.71
- Short % float
- 21.29%
- Days to cover
- 7.3
- SI change
- -7.6%
- 1W
- -25.00%
- 1M
- -35.71%
- vs SPY 1W
- -24.86%
- vs SPY 1M
- -38.22%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 0
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-
REV YoY-
ROE-
EPS YoY-
ROA-70.1%
GROSS-667
OP-5241
NET-4561
[VALUATION]
P/E TTM-0.71
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.69
P/FCF-
EV/EBITDA-0.59
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E211.70
ALTMAN Z-
CURR RATIO6.21
ND/EBITDA-
BETA2.44
Company news
FAQ
- What is LOPJLB’s current signal on HUMA?
- LOPJLB’s latest quantitative signal on Humacyte, Inc. (HUMA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is HUMA in?
- Humacyte, Inc. (HUMA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Humacyte, Inc. (HUMA) do?
- Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vess…